Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CDK 4/6
Pharma
FDA approves breast cancer expansion for Pfizer's Ibrance
Pfizer has gained an FDA expansion for its CDK4/6 blockbuster Ibrance as a maintenance treatment for HR+/HER2+ breast cancer.
Kevin Dunleavy
Jun 24, 2026 2:48pm
Lilly answers Novartis breast cancer rivalry with survival win
Aug 27, 2025 10:59am
Kisqali off to a 'very rapid' launch in early breast cancer: CEO
Jan 31, 2025 11:28am
Pfizer's Ibrance scores in double-positive breast cancer
Dec 12, 2024 8:15am
ASCO: Lilly seeks prostate cancer redemption after Verzenio flop
May 23, 2024 5:00pm
SABCS: Novartis gives update on Kisqali in early breast cancer
Dec 8, 2023 9:15am
